Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01008293
Other study ID # MHE-VSL3-YKJ_AIIMS_ver1
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received November 4, 2009
Last updated June 3, 2013
Start date October 2009
Est. completion date October 2012

Study information

Verified date June 2013
Source CD Pharma India Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority India: Drugs Controller General of IndiaIndia: Indian Council of Medical Research
Study type Interventional

Clinical Trial Summary

This study is a randomized, open, parallel group, active comparator, single center trial. Objectives of the study are hereby given below:

- To study the health related quality of life (HRQOL) in patients with chronic liver disease.

- To assess the prevalence of minimal hepatic encephalopathy (MHE) in patients with chronic liver disease and assessment of HRQOL in patients with MHE.

- To compare the effect of probiotics and lactulose in the treatment of MHE

- To assess the effect of probiotics and lactulose on the HRQOL in patients with MHE.


Description:

The study design would comprise of two parts

1. Part I: Cross sectional study: This part would comprise of the assessment of HRQOL in patients with CLD

1. All the consecutive patients diagnosed as CLD would be enrolled in the study. All these patients would be enrolled from the liver clinics of the department of gastroenterology and those admitted in the gastroenterology ward at AIIMS.

2. Alcohol would be considered to be the cause of CLD, if the patient regularly consumed ≥80g/d of alcohol for five years

3. The staging of cirrhosis would be done according to the Child Pugh classification: A, B and C

4. The causes of CLD would be divided into:- viral hepatitis, alcohol, viral hepatitis combining with alcohol and miscellaneous causes

2. Part II: Prospective randomized controlled trial: In this part the outcome of lactulose and probiotic therapy in the treatment of MHE and its effect on the HRQOL will be compared.

1. All the consecutive patients with CLD without overt encephalopathy would be screened for MHE.

2. All these patients would be enrolled from the liver clinics and the gastroenterology ward, AIIMS.

3. The diagnosis of MHE would be based on abnormal psychometric tests (NCT-A and NCT-B or FCT-A and FCT-B) and /or abnormal P300 auditory event related potentials.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date October 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 80 Years
Eligibility Inclusion Criteria:

- All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively.

Exclusion Criteria:

- Patients with overt hepatic encephalopathy

- Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc

- Malignancy

- History of taking lactulose or probiotics or antibiotics, in the past 6 weeks

- Presence of other neurological or psychiatric disorder

- Patients who underwent shunt surgery for portal hypertension

- History of taking medicines likely to interfere with psychometric performance

- History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks

- Presence of mature cataracts and diabetic retinopathy

- Refused to participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
VSL#3
VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
Lactulose
30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.

Locations

Country Name City State
India Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences New Delhi Delhi

Sponsors (3)

Lead Sponsor Collaborator
CD Pharma India Pvt. Ltd. All India Institute of Medical Sciences, New Delhi, Indian Council of Medical Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL 2 months No
See also
  Status Clinical Trial Phase
Terminated NCT01846806 - The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. N/A
Completed NCT01559519 - Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Phase 4
Recruiting NCT01178372 - Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Phase 4
Completed NCT00740142 - Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy Phase 4
Completed NCT00914056 - A Study of Controlled Lactulose Withdrawal N/A
Completed NCT00558038 - Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy Phase 2
Completed NCT00986895 - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group Phase 1
Completed NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) N/A
Recruiting NCT05539027 - Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy Phase 4
Recruiting NCT04096014 - Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy N/A
Completed NCT05526404 - Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration N/A
Completed NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Enrolling by invitation NCT06367127 - Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
Active, not recruiting NCT05425316 - Speech in Hepatic Encephalopathy (HE)
Recruiting NCT04415294 - Flicker App for Minimal Hepatic Encephalopathy
Not yet recruiting NCT06072521 - Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy Phase 2
Withdrawn NCT02086825 - A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure Phase 3
Completed NCT02636647 - Fecal Transplant in Recurrent Hepatic Encephalopathy Phase 1
Completed NCT01446523 - S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE N/A
Completed NCT01218568 - Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial N/A